Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study.
Chisari CG, Solaro C, Annunziata P, Bergamaschi R, Bianco A, Bonavita S, Brescia Morra V, Bruno Bossio R, Capello E, Castelli L, Cavalla P, Costantino G, Centonze D, Cottone S, Danni MC, Esposito F, Gajofatto A, Gasperini C, Guareschi A, Lanzillo R, Lus G, Maniscalco GT, Matta M, Paolicelli D, Petrucci L, Pontecorvo S, Righini I, Rovaris M, Sessa E, Spinicci G, Spitaleri D, Valentino P, Zaffaroni M, Zappia M, Patti F.
Chisari CG, et al. Among authors: costantino g.
J Neurol Neurosurg Psychiatry. 2020 Sep;91(9):914-920. doi: 10.1136/jnnp-2019-322480. Epub 2020 Jul 13.
J Neurol Neurosurg Psychiatry. 2020.
PMID: 32661083
INTRODUCTION: Delta-delta-tetrahydrocannabinol and cannabidiol (THC:CBD) oromucosal spray is used as an add-on therapy option for moderate to severe multiple sclerosis (MS) spasticity resistant to other medications. Aims of this study were to provide real-life data on long-ter …
INTRODUCTION: Delta-delta-tetrahydrocannabinol and cannabidiol (THC:CBD) oromucosal spray is used as an add-on therapy option for moderate t …